ReviewNature reviews. Gastroenterology & hepatology2022
Breakthroughs in hepatitis C research: from discovery to cure.
Review in Nature reviews. Gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed.
- Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.Clinical pharmacokinetics · 2026Trial
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Sex, Drugs, and the Language of Donor Narratives: Associations With Kidney Acceptance.Transplantation direct · 2026Article
- Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital.Journal of comparative effectiveness research · 2026Review
- Discovery of 5' NAD capped viral RNAs reveals evolutionary divergent 5' metabolite capping across hepaciviruses.Nature communications · 2026Article
- HCV-Induced Hepatocarcinogenesis: Molecular Mechanisms, Persistent Cancer Risk, and Future Perspectives.Biomedicines · 2026Review
- Population-based prevalence and screening gaps of hepatitis C, B and D, Germany, 2020 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Molecular cancer · 2026Review
- The three-decade trajectory of hepatitis C burden among women of reproductive age in China: a retrospective and predictive study.Virology journal · 2026Article
- Characterization of the virus-host RNA-RNA interactome across important human pathogenic RNA viruses.PLoS pathogens · 2026Article
- Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies.Journal of virology · 2026Article
- Dissecting incidence and mortality inequalities of six types of liver diseases in 39 alcohol-dominant countries and 93 virus-dominant countries under the aging context: Insights from the Global Burden of Disease Study 2021.Translational oncology · 2026Article
- Generation of a HiBiT-expressing recombinant rat hepacivirus supporting both in vivo and in vitro infection.PLoS pathogens · 2026Article
- Mass hepatitis C virus screening among persons in custody in Hong Kong: a modelling cost-effectiveness analysis based on a prospective cohort study.The Lancet regional health. Western Pacific · 2026Article
- Periodontitis and Chronic Liver Disease: Mechanistic Insights Focusing onMicroorganisms · 2026Review
- An analysis of the global, regional, and national burden of liver cirrhosis in older adults from 1990 to 2021.Medicine · 2026Article
- Screening and care of patients with graft cirrhosis following liver transplantation.Canadian liver journal · 2026Article
- Preexisting Liver Disease and Pregnancy: Optimizing Care to Optimize Outcomes.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Review
- Treatment with Direct-Acting Antivirals in Patients with HCV Infection After Liver Transplantation.Journal of clinical medicine · 2026Article
- Hepatitis C virus-associated B-cell non-Hodgkin lymphomas: immune evasion, multistep lymphomagenesis, and candidate biomarkers for risk stratification and disease monitoring.Frontiers in immunology · 2026Review
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the 1970s, an unknown virus was suspected for documented cases of transfusion-associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious transmissible agent was identified and named hepatitis C virus (HCV) and, soon enough, the first diagnostic HCV antibody test was developed, which led to a dramatic decrease in new infections. Today, HCV infection remains a global health burden and a major cause of liver cirrhosis, hepatocellular carcinoma and liver transplantation. However, tremendous advances have been made over the decades, and HCV became the first curable, chronic viral infection. The introduction of direct antiviral agents revolutionized antiviral treatment, leading to viral eradication in more than 98% of all patients infected with HCV. This Perspective discusses the history of HCV research, which reads like a role model for successful translational research: starting from a clinical observation, specific therapeutic agents were developed, which finally were implemented in national and global elimination programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.